The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Subgroup analyses in the CLEAR study of lenvatinib plus pembrolizumab versus sunitinib in RCC
Viktor Grünwald, MD, University Hospital Essen, Essen, Germany, shares the efficacy findings of lenvatinib plus pembrolizumab versus sunitinib in selected subgroups of the CLEAR trial in advanced renal cell carcinoma (RCC). The Phase III CLEAR study (NCT02811861) demonstrated that combined lenvatinib plus pembrolizumab had significant survival benefits when compared to single-agent sunitinib in first-line advanced RCC. Progression-free survival and overall survival were analyzed by IMDC risk group, which found lenvatinib plus pembrolizumab to be favorable across all risk groups. Patients with target kidney lesions were also assessed individually, where it was demonstrated that lenvatinib plus pembrolizumab conferred survival benefits similar to those seen in the overall population. Target lesion reduction was shown to be strongly prognostic, which patients achieving greater than 75% reduction in the lenvatinib plus pembrolizumab arm showing similar overall survival rates to patients with a confirmed complete response. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Viktor Grünwald, MD has received advisory roles for BMS, MSD, EISAI, EUSAPharm, Merck-Serono, Nanobiotix, Pfizer and Roche; speaker’s honoraria for AstraZeneca, BMS, MSD, EISAI, Ipsen, Janssen-Cilag, Merck-Serono, Pfizer and Roche; stocks in AstraZeneca, BMS, MSD and SeattleGenetics; research grants from AstraZeneca, BMS, MSD, Ipsen and Pfizer; is a steering committee member for BMS, EISAI, Ipsen, Novartis and PharmaMar.
